- Home
- BMEA vs FONR Comparison
BMEA vs FONR Comparison
Compare BMEA & FONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- FONR
- Stock Information
- Founded
- BMEA 2017
- FONR 1978
- Country
- BMEA United States
- FONR United States
- Employees
- BMEA N/A
- FONR N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BMEA Health Care
- FONR Health Care
- Exchange
- BMEA Nasdaq
- FONR Nasdaq
- Market Cap
- BMEA 65.8M
- FONR 77.1M
- IPO Year
- BMEA 2021
- FONR 1987
- Fundamental
- Price
- BMEA $1.44
- FONR $14.50
- Analyst Decision
- BMEA Strong Buy
- FONR
- Analyst Count
- BMEA 11
- FONR 0
- Target Price
- BMEA $27.60
- FONR N/A
- AVG Volume (30 Days)
- BMEA 703.1K
- FONR 42.9K
- Earning Date
- BMEA 05-05-2025
- FONR 05-15-2025
- Dividend Yield
- BMEA N/A
- FONR N/A
- EPS Growth
- BMEA N/A
- FONR N/A
- EPS
- BMEA N/A
- FONR 1.28
- Revenue
- BMEA N/A
- FONR $103,018,089.00
- Revenue This Year
- BMEA N/A
- FONR N/A
- Revenue Next Year
- BMEA N/A
- FONR N/A
- P/E Ratio
- BMEA N/A
- FONR $11.36
- Revenue Growth
- BMEA N/A
- FONR 0.29
- 52 Week Low
- BMEA $1.29
- FONR $12.00
- 52 Week High
- BMEA $13.07
- FONR $18.68
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- FONR 67.86
- Support Level
- BMEA $1.29
- FONR $13.33
- Resistance Level
- BMEA $1.52
- FONR $14.59
- Average True Range (ATR)
- BMEA 0.14
- FONR 0.57
- MACD
- BMEA 0.01
- FONR 0.18
- Stochastic Oscillator
- BMEA 28.17
- FONR 96.17
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.